Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C

Eiichi Ogawa, Norihiro Furusyo, motohiro shimizu, Takeshi Ihara, Takeo Hayashi, Yuji Harada, Kazuhiro Toyoda, Murata Masayuki, Jun Hayashi

研究成果: ジャーナルへの寄稿記事

6 引用 (Scopus)

抄録

Background: Liver fibrosis remains one of the most important predictors of sustained virological response (SVR) in this era of direct-acting antiviral treatment of chronic hepatitis C. We compare non-invasive fibrosis assessment with liver biopsy (METAVIR) in terms of their ability to predict SVR by telaprevir (TVR)-based triple therapy. Methods: This prospective study consisted of 108 patients with chronic HCV genotype 1 infection who received TVR in combination with pegylated interferon (PEG-IFN)-α2b and ribavirin (RBV). Non-invasive fibrosis data included transient elastography (FibroScan), FIB-4 index and aspartate aminotransferase to platelet ratio index (APRI). Results: SVR was achieved by 84.3% of the patients by intention-to-treat analysis. In contrast to the high SVR rates for treatment-naive patients (87.1%, 27 of 31) and patients who previously relapsed (97.9%, 46 of 47), the SVR rate of prior partial/null responders was significantly lower (60.0%, 18 of 30). The impact of fibrosis on SVR was greater for prior partial/null responders, and fibrosis data, including both METAVIR score and non-invasive fibrosis assessments, were useful for predicting SVR. The METAVIR score (area under the receiver operating characteristic curve [AUROC] 0.91, cutoff ≤F2), FibroScan values (AUROC 0.99, cutoff ≤10.0 kPa), FIB-4 index (AUROC 0.91, cutoff ≤3.5) and APRI (AUROC 0.91, cutoff ≤0.80) were shown to have equal, excellent predictive power. Conclusions: An alternative to METAVIR score by liver biopsy, non-invasive fibrosis assessments are useful options for predicting SVR by prior partial or null responders in TVR-based triple therapy.

元の言語英語
ページ(範囲)185-192
ページ数8
ジャーナルAntiviral Therapy
20
発行部数2
DOI
出版物ステータス出版済み - 1 1 2015

Fingerprint

Ribavirin
Chronic Hepatitis C
Interferons
Fibrosis
ROC Curve
Blood Platelets
Biopsy
Elasticity Imaging Techniques
Intention to Treat Analysis
Liver
Therapeutics
Aspartate Aminotransferases
Transaminases
Liver Cirrhosis
Antiviral Agents
telaprevir
Genotype
Prospective Studies
Infection

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

これを引用

Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C. / Ogawa, Eiichi; Furusyo, Norihiro; shimizu, motohiro; Ihara, Takeshi; Hayashi, Takeo; Harada, Yuji; Toyoda, Kazuhiro; Masayuki, Murata; Hayashi, Jun.

:: Antiviral Therapy, 巻 20, 番号 2, 01.01.2015, p. 185-192.

研究成果: ジャーナルへの寄稿記事

Ogawa, Eiichi ; Furusyo, Norihiro ; shimizu, motohiro ; Ihara, Takeshi ; Hayashi, Takeo ; Harada, Yuji ; Toyoda, Kazuhiro ; Masayuki, Murata ; Hayashi, Jun. / Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C. :: Antiviral Therapy. 2015 ; 巻 20, 番号 2. pp. 185-192.
@article{a45b9a9c929c41d1ad1a962d9d9a68ad,
title = "Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C",
abstract = "Background: Liver fibrosis remains one of the most important predictors of sustained virological response (SVR) in this era of direct-acting antiviral treatment of chronic hepatitis C. We compare non-invasive fibrosis assessment with liver biopsy (METAVIR) in terms of their ability to predict SVR by telaprevir (TVR)-based triple therapy. Methods: This prospective study consisted of 108 patients with chronic HCV genotype 1 infection who received TVR in combination with pegylated interferon (PEG-IFN)-α2b and ribavirin (RBV). Non-invasive fibrosis data included transient elastography (FibroScan), FIB-4 index and aspartate aminotransferase to platelet ratio index (APRI). Results: SVR was achieved by 84.3{\%} of the patients by intention-to-treat analysis. In contrast to the high SVR rates for treatment-naive patients (87.1{\%}, 27 of 31) and patients who previously relapsed (97.9{\%}, 46 of 47), the SVR rate of prior partial/null responders was significantly lower (60.0{\%}, 18 of 30). The impact of fibrosis on SVR was greater for prior partial/null responders, and fibrosis data, including both METAVIR score and non-invasive fibrosis assessments, were useful for predicting SVR. The METAVIR score (area under the receiver operating characteristic curve [AUROC] 0.91, cutoff ≤F2), FibroScan values (AUROC 0.99, cutoff ≤10.0 kPa), FIB-4 index (AUROC 0.91, cutoff ≤3.5) and APRI (AUROC 0.91, cutoff ≤0.80) were shown to have equal, excellent predictive power. Conclusions: An alternative to METAVIR score by liver biopsy, non-invasive fibrosis assessments are useful options for predicting SVR by prior partial or null responders in TVR-based triple therapy.",
author = "Eiichi Ogawa and Norihiro Furusyo and motohiro shimizu and Takeshi Ihara and Takeo Hayashi and Yuji Harada and Kazuhiro Toyoda and Murata Masayuki and Jun Hayashi",
year = "2015",
month = "1",
day = "1",
doi = "10.3851/IMP2805",
language = "English",
volume = "20",
pages = "185--192",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "2",

}

TY - JOUR

T1 - Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C

AU - Ogawa, Eiichi

AU - Furusyo, Norihiro

AU - shimizu, motohiro

AU - Ihara, Takeshi

AU - Hayashi, Takeo

AU - Harada, Yuji

AU - Toyoda, Kazuhiro

AU - Masayuki, Murata

AU - Hayashi, Jun

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Liver fibrosis remains one of the most important predictors of sustained virological response (SVR) in this era of direct-acting antiviral treatment of chronic hepatitis C. We compare non-invasive fibrosis assessment with liver biopsy (METAVIR) in terms of their ability to predict SVR by telaprevir (TVR)-based triple therapy. Methods: This prospective study consisted of 108 patients with chronic HCV genotype 1 infection who received TVR in combination with pegylated interferon (PEG-IFN)-α2b and ribavirin (RBV). Non-invasive fibrosis data included transient elastography (FibroScan), FIB-4 index and aspartate aminotransferase to platelet ratio index (APRI). Results: SVR was achieved by 84.3% of the patients by intention-to-treat analysis. In contrast to the high SVR rates for treatment-naive patients (87.1%, 27 of 31) and patients who previously relapsed (97.9%, 46 of 47), the SVR rate of prior partial/null responders was significantly lower (60.0%, 18 of 30). The impact of fibrosis on SVR was greater for prior partial/null responders, and fibrosis data, including both METAVIR score and non-invasive fibrosis assessments, were useful for predicting SVR. The METAVIR score (area under the receiver operating characteristic curve [AUROC] 0.91, cutoff ≤F2), FibroScan values (AUROC 0.99, cutoff ≤10.0 kPa), FIB-4 index (AUROC 0.91, cutoff ≤3.5) and APRI (AUROC 0.91, cutoff ≤0.80) were shown to have equal, excellent predictive power. Conclusions: An alternative to METAVIR score by liver biopsy, non-invasive fibrosis assessments are useful options for predicting SVR by prior partial or null responders in TVR-based triple therapy.

AB - Background: Liver fibrosis remains one of the most important predictors of sustained virological response (SVR) in this era of direct-acting antiviral treatment of chronic hepatitis C. We compare non-invasive fibrosis assessment with liver biopsy (METAVIR) in terms of their ability to predict SVR by telaprevir (TVR)-based triple therapy. Methods: This prospective study consisted of 108 patients with chronic HCV genotype 1 infection who received TVR in combination with pegylated interferon (PEG-IFN)-α2b and ribavirin (RBV). Non-invasive fibrosis data included transient elastography (FibroScan), FIB-4 index and aspartate aminotransferase to platelet ratio index (APRI). Results: SVR was achieved by 84.3% of the patients by intention-to-treat analysis. In contrast to the high SVR rates for treatment-naive patients (87.1%, 27 of 31) and patients who previously relapsed (97.9%, 46 of 47), the SVR rate of prior partial/null responders was significantly lower (60.0%, 18 of 30). The impact of fibrosis on SVR was greater for prior partial/null responders, and fibrosis data, including both METAVIR score and non-invasive fibrosis assessments, were useful for predicting SVR. The METAVIR score (area under the receiver operating characteristic curve [AUROC] 0.91, cutoff ≤F2), FibroScan values (AUROC 0.99, cutoff ≤10.0 kPa), FIB-4 index (AUROC 0.91, cutoff ≤3.5) and APRI (AUROC 0.91, cutoff ≤0.80) were shown to have equal, excellent predictive power. Conclusions: An alternative to METAVIR score by liver biopsy, non-invasive fibrosis assessments are useful options for predicting SVR by prior partial or null responders in TVR-based triple therapy.

UR - http://www.scopus.com/inward/record.url?scp=84937553559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937553559&partnerID=8YFLogxK

U2 - 10.3851/IMP2805

DO - 10.3851/IMP2805

M3 - Article

VL - 20

SP - 185

EP - 192

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 2

ER -